Bibliography
- TAGA T, HIBI M, HIRATA Y et al.: Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 58:573-581.
- MULLBERG J, SCHOOLTINK H, STOYAN T et al.: The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. (1993) 23:473-480.
- HORIUCHI S, KOYANAGI Y, ZHOU Y et al.: Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur. J. Immunol. (1994) 24:1945-1948.
- HIBI M, MURAKAMI M, SAITO M et al.: Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 63:1149-1157.
- IP NY, NYE SH, BOULTON TG et al.: CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell (1992) 69:1121-1132.
- GEARING DP, COMEAU MR, FRIEND DJ et al.: The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science (1992) 255:1434-1437.
- LIU J, MODRELL B, ARUFFO A et al.: Interleukin-6 signal transducer gp130 mediates oncostatin M signaling. J. Biol. Chem. (1992) 267:16763-16766.
- YIN T, TAGA T, TSANG ML et al.: Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J. Immunol. (1993) 151:2555-2561.
- PENNICA D, SHAW KJ, SWANSON TA et al.: Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J. Biol. Chem. (1995) 270:10915-10922.
- ROSE-JOHN S, WAETZIG GH, SCHELLER J et al.: The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther. Targets (2007) 11(5):613-624.
- SHOUDA T, YOSHIDA T, HANADA T et al.: Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. (2001) 108:1781-1788.
- HURST SM, WILKINSON TS, MCLOUGHLIN RM et al.: Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 14:705-714.
- MARIN V, MONTERO-JULIAN FA, GRES S et al.: The IL-6-soluble IL-6Rα autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation:an experimental model involving thrombin. J. Immunol. (2001) 167:3435-3442.
- YAMASHIRO S, KAMOHARA H, YOSHIMURA T: MCP-1 is selectively expressed in the late phase by cytokine-stimulated human neutrophils:TNF-α plays a role in maximal MCP-1 mRNA expression. J. Leukoc. Biol. (1999) 65:671-679.
- BELLINGAN GJ, CALDWELL H, HOWIE SE et al.: In vivo fate of the inflammatory macrophage during the resolution of inflammation:inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J. Immunol. (1996) 157:2577-2585.
- GABAY C: Interleukin-6 and chronic inflammation. Arthritis Res. Ther. (2006) 8(Suppl. 2):S3.
- GABAY C, KUSHNER I: Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. (1999) 340:448-454.
- KOPF M, BAUMANN H, FREER G et al.: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 368:339-342.
- FATTORI E, CAPPELLETTI M, COSTA P et al.: Defective inflammatory response in interleukin 6-deficient mice. J. Exp. Med. (1994) 180:1243-1250.
- Ogawa M: IL6 and haematopoietic stem cells. Res. Immunol. (1992) 143:749-751.
- FINCK BK, CHAN B, WOFSY D: Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest. (1994) 94:585-591.
- PASARE C, MEDZHITOV R: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 299:1033-1036.
- KIMURA A, NAKA T, KISHIMOTO T: IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. USA (2007) 104:12099-12104.
- BROMBERG J, DARNELL JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene (2000) 19:2468-2473.
- DIAZ N, MINTON S, COX C et al.: Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin. Cancer Res. (2006) 12:20-28.
- GRITSKO T, WILLIAMS A, TURKSON J et al.: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. (2006) 12:11-19.
- IKUTA K, TAKEMURA K, KIHARA M et al.: Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. Oncol. Rep. (2005) 13:217-222.
- MAINI RN, TAYLOR PC, SZECHINSKI J et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. (2006) 54:2817-2829.
- WOO P, WILKINSON N, PRIEUR AM et al.: Open label Phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis:proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. (2005) 7:R1281-R1288.
- SU JL, LAI KP, CHEN CA et al.: A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res. (2005) 65:4827-4835.